Eek D, Krohe M, Mazar I, Horsfield A, Pompilus F, Friebe R, et al. Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: a review of the literature. Patient Prefer Adherence. 2016;10:1609–21.

PubMed  PubMed Central  Article  Google Scholar 

Cinar D, Tas D. Cancer in the elderly. North Clin Istanb. 2015;2(1):73–80.

PubMed  PubMed Central  Google Scholar 

Bhatt VR. Cancer in older adults: understanding cause and effects of chemotherapy-related toxicities. Future Oncol. 2019;15(22):2557–60.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Dunn C, Wilson A, Sitas F. Older cancer patients in cancer clinical trials are underrepresented. Systematic literature review of almost 5000 meta- and pooled analyses of phase III randomized trials of survival from breast, prostate and lung cancer. Cancer Epidemiol. 2017;51:113–7.

PubMed  Article  Google Scholar 

François E, Azria D, Gourgou-Bourgade S, Jarlier M, Martel-Laffay I, Hennequin C, et al. Results in the elderly with locally advanced rectal cancer from the ACCOR12/PRODIGE 2 phase III trial: tolerance and efficacy. Radiother Oncol. 2014;110(1):144–9.

PubMed  Article  Google Scholar 

Sastre J, Aranda E, Massutí B, Tabernero J, Chaves M, Abad A, et al. Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: comparative outcomes from the 03-TTD-01 phase III study. Crit Rev Oncol Hematol. 2009;70(2):134–44.

PubMed  Article  Google Scholar 

Leicher LW, de Graaf JC, Coers W, Tascilar M, de Groot JWB. Tolerability of Capecitabine Monotherapy in Metastatic Colorectal Cancer: A Real-World Study. Drugs R D. 2017;17(1):117–24.

CAS  PubMed  Article  Google Scholar 

Comella P, Natale D, Farris A, Gambardella A, Maiorino L, Massidda B, et al. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108. Cancer. 2005;104(2):282–9.

CAS  PubMed  Article  Google Scholar 

Mason M, Harris MR, Greer JA, Jiang Y. A Concept Analysis of Oral Anticancer Agent Self-management. Cancer Nurs. 2022;45(2):E374–87.

PubMed  Article  Google Scholar 

Prasad V, Massey PR, Fojo T. Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients. J Clin Oncol. 2014;32(15):1620–9.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Wang Y, Wang L, Rastegar-Mojarad M, Moon S, Shen F, Afzal N, et al. Clinical information extraction applications: A literature review. J Biomed Inform. 2018;77:34–49.

PubMed  Article  Google Scholar 

Jiang Y, Wickersham KE, Zhang X, Barton DL, Farris KB, Krauss JC, et al. Side Effects, Self-Management Activities, and Adherence to Oral Anticancer Agents. Patient Prefer Adherence. 2019;13:2243–52.

PubMed  PubMed Central  Article  Google Scholar 

Kuhn M, Letunic I, Jensen LJ, Bork P. The SIDER database of drugs and side effects. Nucleic Acids Res. 2016;44(D1):D1075-1079.

CAS  PubMed  Article  Google Scholar 

U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. NIH. 2017; Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm

National Cancer Institute. Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). NIH. 2017; Available from: https://healthcaredelivery.cancer.gov/pro-ctcae/

Flannery MA, Culakova E, Canin BE, Peppone L, Ramsdale E, Mohile SG. Understanding treatment tolerability in older adults with cancer. J Clin Oncol. 2021;39(19):2150–63.

PubMed  PubMed Central  Article  Google Scholar 

Basch E, Iasonos A, McDonough T, Barz A, Culkin A, Kris MG, Scher HI, Schrag D. Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol. 2006;7(11):903–9.

PubMed  Article  Google Scholar 

Fares CM, Williamson TJ, Theisen MK, Cummings A, Bornazyan K, Carroll J, Spiegel ML, Stanton AL, Garon EB. Low concordance of patient-reported outcomes with clinical and clinical trial documentation. JCO Clinical Cancer Inform. 2018;2:1–2.

Article  Google Scholar 

Chandwani KD, Zhao F, Morrow GR, Deshields TL, Minasian LM, Manola J, Fisch MJ. Lack of patient-clinician concordance in cancer patients: its relation with patient variables. J Pain Symptom Manage. 2017;53(6):988–98.

PubMed  PubMed Central  Article  Google Scholar 

Basch E, Rogak LJ, Dueck AC. Methods for Implementing and Reporting Patient-reported Outcome (PRO) Measures of Symptomatic Adverse Events in Cancer Clinical Trials. Clin Ther. 2016;38(4):821–30.

PubMed  PubMed Central  Article  Google Scholar 

Garcia SF, Wortman K, Cella D, Wagner LI, Bass M, Kircher S, Pearman T, Penedo FJ. Implementing electronic health record–integrated screening of patient-reported symptoms and supportive care needs in a comprehensive cancer center. Cancer. 2019;125(22):4059–68.

PubMed  Article  Google Scholar 

Hassett MJ, Cronin C, Tsou TC, Wedge J, Bian J, Dizon DS, Hazard-Jenkins H, Osarogiagbon RU, Wong S, Basch E, Austin T. eSyM: An Electronic Health Record-Integrated Patient-Reported Outcomes-Based Cancer Symptom Management Program Used by Six Diverse Health Systems. JCO Clinical Cancer Inform. 2021;6:e2100137.

Google Scholar 

Bartlett VL, Dhruva SS, Shah ND, Ryan P, Ross JS. Feasibility of using real-world data to replicate clinical trial evidence. JAMA Netw Open. 2019;2(10):e1912869.

PubMed  PubMed Central  Article  Google Scholar 

Lassere Y, Hoff P. Management of hand-foot syndrome in patients treated with capecitabine (Xeloda®). Eur J Oncol Nurs. 2004;1(8):S31-40.

Article  Google Scholar 

Gressett SM, Stanford BL, Hardwicke F. Management of hand-foot syndrome induced by capecitabine. J Oncol Pharm Pract. 2006;12(3):131–41.

CAS  PubMed  Article  Google Scholar 

Meulendijks D, van Hasselt JC, Huitema AD, van Tinteren H, Deenen MJ, Beijnen JH, Cats A, Schellens JH. Renal function, body surface area, and age are associated with risk of early-onset fluoropyrimidine-associated toxicity in patients treated with capecitabine-based anticancer regimens in daily clinical care. Eur J Cancer. 2016;1(54):120–30.

Article  CAS  Google Scholar 

Karthikeyan G, Jumnani D, Prabhu R, Manoor UK, Supe SS. Prevalence of fatigue among cancer patients receiving various anticancer therapies and its impact on quality of life: a cross-sectional study. Indian J Palliat Care. 2012;18(3):165.

PubMed  PubMed Central  Article  Google Scholar 

Soones T, Ombres R, Escalante C. An update on cancer-related fatigue in older adults: A narrative review. J Geriatr Oncol. 2021;S1879–4068(21):00169–77.

Poort H, Jacobs JM, Pirl WF, Temel JS, Greer JA. Fatigue in patients on oral targeted or chemotherapy for cancer and associations with anxiety, depression, and quality of life. Palliat Support Care. 2020;18(2):141–7.

PubMed  PubMed Central  Article  Google Scholar 

Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol. 2002;13(4):566–75.

CAS  PubMed  Article  Google Scholar 

van Beek MWH, Roukens M, Jacobs WCH, Timmer-Bonte JNH, Kramers C. Real-World Adverse Effects of Capecitabine Toxicity in an Elderly Population. Drugs Real World Outcomes. 2018;5(3):161–7.

PubMed  PubMed Central  Article  Google Scholar 

Kwakman JJM, Elshot YS, Punt CJA, Koopman M. Management of cytotoxic chemotherapy-induced hand-foot syndrome. Oncol Rev. 2020;14(1):442.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Cataldo JK, Paul S, Cooper B, Skerman H, Alexander K, Aouizerat B, Blackman V, Merriman J, Dunn L, Ritchie C, Yates P. Differences in the symptom experience of older versus younger oncology outpatients: a cross-sectional study. BMC Cancer. 2013;13(1):1–6.

Article  Google Scholar 

Gijzel SM, Whitson HE, van de Leemput IA, Scheffer M, van Asselt D, Rector JL, OldeRikkert MG, Melis RJ. Resilience in clinical care: getting a grip on the recovery potential of older adults. J Am Geriatr Soc. 2019;67(12):2650–7.

PubMed  PubMed Central  Article  Google Scholar 

Howard JS, Mattacola CG, Howell DM, Lattermann C. Response shift theory: an application for health-related quality of life in rehabilitation research and practice. J Allied Health. 2011;40(1):31–8.

PubMed  Google Scholar 

Vanier A, Oort FJ, McClimans L, Ow N, Gulek BG, Böhnke JR, Sprangers M, Sébille V, Mayo N. Response shift in patient-reported outcomes: definition, theory, and a revised model. Qual Life Res. 2021;30(12):3309–22.

PubMed  PubMed Central  Article  Google Scholar 

Cho Y, Zhang H, Harris MR, Gong Y, Smith EL, Jiang Y. Acceptance and use of home-based electronic symptom self-reporting systems in patients with cancer: Systematic review. J Med Internet Res. 2021;23(3):e24638.

PubMed  PubMed Central  Article  Google Scholar 

Jiang Y, Yang G. Enhancing Safety via Medication Self-Management and Timely Reporting. Studies in health technology and informatics. 2021;12(284):463.

Google Scholar 

Tantoy IY, Cataldo JK, Aouizerat BE, Dhruva A, Miaskowski C. A review of the literature on multiple co-occurring symptoms in patients with colorectal cancer who received chemotherapy alone or chemotherapy with targeted therapies. Cancer Nurs. 2016;39(6):437–45.

PubMed  PubMed Central  Article  Google Scholar 

Herrstedt J, Lindberg S, Petersen PC. Prevention of Chemotherapy-Induced Nausea and Vomiting in the Older Patient: Optimizing Outcomes. Drugs Aging. 2021;9:1–21.

Google Scholar 

Rizzo A, Nannini M, Novelli M, Dalia Ricci A, Scioscio VD, Pantaleo MA. Dose reduction and discontinuation of standard-dose regorafenib associated with adverse drug events in cancer patients: a systematic review and meta-analysis. Ther Adv Med Oncol. 2020;12:1758835920936932.

PubMed  PubMed Central  Article  Google Scholar 

Rosati G, Lonardi S, Galli F, Di Bartolomeo M, Ronzoni M, Zampino MG, et al. Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial. Eur J Cancer. 2021;148:190–201.